A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The Sponsor's decision to terminate the SBC-103 program was reached after review of the data from all interventional clinical studies of SBC-103.

Conditions

Mucopolysaccharidosis III, Type B (MPS IIIB)
Sanfilippo B

Interventions

DRUG: SBC-103

Sponsor

Alexion Pharmaceuticals, Inc.